Format

Send to

Choose Destination
Jpn J Clin Oncol. 2016 Jun;46(6):502-6. doi: 10.1093/jjco/hyw033. Epub 2016 Mar 22.

An epidermal growth factor receptor exon 19 mutation in a mucin-producing gastric cancer sample from a Chinese patient.

Author information

1
Laboratory Center, The Second Affiliated Hospital of Dalian Medical University, Dalian Department of Pathology, Affiliated Zhongshan Hospital of Dalian University, Dalian.
2
Laboratory Center, The Second Affiliated Hospital of Dalian Medical University, Dalian.
3
Department of Pathology, The Third People's Hospital of Dalian, Dalian.
4
Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, Dalian, PR China.
5
Laboratory Center, The Second Affiliated Hospital of Dalian Medical University, Dalian lvshen1956@126.com.

Abstract

OBJECTIVE:

To determine whether a subgroup of gastric cancer patients might benefit from epidermal growth factor receptor-tyrosine kinase inhibitors.

METHODS:

A total of 103 gastric cancer samples were collected for this study. High-resolution melting and deoxyribonucleic acid sequencing were used to detect epidermal growth factor receptor mutations in exons 19 and 21.

RESULTS:

Polymerase chain reaction-high-resolution melting was successfully performed on all 103 samples. Aberrant melting curves were found in only one sample. Sanger sequencing revealed a 15 bp deletion (c.2235_2249del; p.Glu746_Ala750del) in epidermal growth factor receptor exon 19. The sample was from a male patient, and the pathological diagnosis was a mucin-producing gastric cancer with lymph node metastasis. To date, this is the first report on epidermal growth factor receptor exon 19 mutation in gastric cancer.

CONCLUSIONS:

An epidermal growth factor receptor mutation in exon 19 was identified in mucin-producing gastric cancer sample from a male patient. This mutation indicates that the small subgroup of patients with mucin-producing gastric cancer might benefit from epidermal growth factor receptor-tyrosine kinase inhibitors.

KEYWORDS:

EGFR; gastric cancer; gene mutation; tyrosine kinase inhibitors

PMID:
27004903
DOI:
10.1093/jjco/hyw033
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center